

## **CD4+CCR6+ T cells dominate the BCG-induced transcriptional signature**

Akul Singhania<sup>1,†</sup>, Paige Dubelko<sup>1,†</sup>, Rebecca Kuan<sup>1</sup>, William D. Chronister<sup>1</sup>, Kaylin Muskat<sup>1</sup>, Jyotirmoy Das<sup>2</sup>, Elizabeth J. Phillips<sup>3,4</sup>, Simon A. Mallal<sup>3,4</sup>, Grégory Seumois<sup>1</sup>, Pandurangan Vijayanand<sup>1</sup>, Alessandro Sette<sup>1,5</sup>, Maria Lerm<sup>2</sup>, Bjoern Peters<sup>1,5</sup>, Cecilia S. Lindestam Arlehamn<sup>1,\*</sup>

<sup>1</sup> Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA

<sup>2</sup> Division of Infection and Inflammation, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden

<sup>3</sup> Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA 6150, Australia

<sup>4</sup> Vanderbilt University School of Medicine, Nashville, TN 37235, USA

<sup>5</sup> Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA

<sup>†</sup> Co-first authors


\* Corresponding author

Cecilia S. Lindestam Arlehamn

Email: [cecilia@lji.org](mailto:cecilia@lji.org)


## Supplementary material

### Supplementary Figures




Supplementary Figure 1

**SUPPLEMENTARY FIGURE 1. Cell subset frequencies pre- and post- BCG vaccination.** **a-c** Frequencies of cell subsets pre- (open circles) and post- (closed circles) BCG vaccination. Each point represents one participant (n=10), Wilcoxon matched pair signed rank test. **a** Major lymphocyte subsets not shown in figure 3. **b, c** Memory T cell subsets defined by CCR7 and CD45RA; Naïve cells (CD45RA+CCR7+), Tcm (CD45RA-CCR7+), Tem (CD45RA-CCR7-), and Temra (CD45RA+CCR7-). **b** CD4 T cell subsets. **c** CD8 T cell subsets.



Supplementary Figure 2


**SUPPLEMENTARY FIGURE 2. Characterization of the DNAm alterations.** **a.** Cell type frequency analysis applying the Houseman algorithm to the DNA methylation dataset of samples obtained pre- and post- BCG vaccination. The y-axis shows the frequency of cell types in the group of samples and the x-axis denotes the calculated cell type in the PBMC sample. Student's t-test. **b.** Volcano plot illustrating the hyper- and hypomethylated CpGs. The x-axis represents the mean methylation difference (mmd). The y-axis denotes the significance level (p-value) at the logarithm scale. The solid horizontal line sets the threshold of  $p < 0.05$  and the dashed vertical lines used for the cut-off value,  $mmd \geq |0.1|$ . **c.** Number of CpGs present in different chromosomal locations for hypermethylated (red) and hypomethylated (blue) CpGs.



Supplementary Figure 3


**SUPPLEMENTARY FIGURE 3. Cell subset-specific gene signatures pre- and post- BCG vaccination**

**a, b** Boxplots of RNA-seq data depicting the sum of log<sub>2</sub> expression values (variance stabilizing transformation, VST) for all genes in the (a) MAIT cell signature, and (b) Th1\* cell signature. Empty and filled boxplot represent pre- and post-vaccination, respectively, and color represents stimulation condition. Each dot represents an individual donor.




Supplementary Figure 4

**SUPPLEMENTARY FIGURE 4.** Representative volcano plots showing clonotype expansion in response to BCG stimulation. Analysis from Donor 1489 is shown. Column 1 indicates clonotypes expanded upon BCG stimulation in each replicate, pre- and post- vaccination. Column 2 indicates only those clonotypes that expanded upon BCG stimulation in both replicates, pre- and post- vaccination. Column 3 further indicates a subset to show only those clonotypes that expanded upon BCG stimulation in both replicates, but not in MTB300 or Tetanus stimulation, pre- and post- vaccination.




Supplementary Figure 5

**SUPPLEMENTARY FIGURE 5.** Representative volcano plots showing clonotype expansion in response to MTB300 and Tetanus stimulation. Analysis from Donor 1489 is shown. Column 1 indicates clonotypes expanded upon MTB300 stimulation in each replicate, pre- and post-vaccination. Column 2 indicates only those clonotypes that expanded upon MTB300 stimulation in both replicates, pre- and post- vaccination. Column 3 indicates clonotypes expanded upon Tetanus stimulation in each replicate, pre- and post- vaccination. Column 4 indicates only those clonotypes that expanded upon Tetanus stimulation in both replicates, pre- and post- vaccination.



Supplementary Figure 6

**SUPPLEMENTARY FIGURE 6. Comparison of TCRMatch scores within and across T cell repertoires from individuals pre- and post-BCG vaccination.** **a-c** Comparison of CDR3 $\beta$  similarity within individuals before and after BCG vaccination ( $n=8$ ) and expanded or unexpanded in response to BCG stimulus in vitro, as assessed by the fraction of scores **(a)** >0.84, **(b)** >0.90, **(c)** >0.97. 100 random samplings of each individual's unexpanded TCRs are represented by violin plots. Gray lines indicate first, second and third quartiles. One-tailed Mann-Whitney test. **d** Comparison of CDR3 $\beta$  similarity in expanded T cells across individuals pre- and post-BCG vaccination. One-tailed Mann-Whitney test. **e** Comparison of the fraction of TCRMatch scores >0.97 between two individuals and the number of HLA class II alleles shared by the individuals. One-tailed Spearman test.



**SUPPLEMENTARY FIGURE 7. Gating strategies for flow cytometry analyses and cell sorting.** **a** Th-subset gating, **b** non-conventional T cells, MAITs were defined as MR1 5-OP-RU tetramer+CD4-V $\alpha$ 24- $\gamma$  $\delta$ TCR-V $\alpha$ 7.2+CD161+. A representative control 6-FP MR1 tetramer stain is shown for comparison. **c** Intracellular cytokine staining. BCG stimulated and unstimulated samples for both IL-17 and IFN $\gamma$  is shown. **d** Cell sorting of PBMC (excluding doublets) and live memory CD4 T cells.

## **Supplementary Tables**

Supplementary table 1-4 provided as excel files

**SUPPLEMENTARY TABLE 1** Differentially expressed genes identified in the different comparisons for PBMC and CD4 memory T cells.

**SUPPLEMENTARY TABLE 2** Pathway enrichment for upregulated genes in PBMCs and CD4 memory T cells.

**SUPPLEMENTARY TABLE 3** MAIT and Th1\* signatures

**SUPPLEMENTARY TABLE 4** TCR repertoire dataset

**SUPPLEMENTARY TABLE 5** Number of clonotypes per subject

|                | Subject | Total Clonotypes |             | Clonotypes expanded upon BCG stimulation |             | Clonotypes expanded in both replicates |                |               |                  |                     |    |
|----------------|---------|------------------|-------------|--|-------------|--|----------------|---------------|------------------|---------------------|----|
|                |         | Replicate 1      | Replicate 2 | Replicate 1                              | Replicate 2 | BCG stim                               | BCG stim - tet | BCG stim only | MTB300 stim only | BCG and MTB300 stim |    |
| PRE            | 1489    | 30544            | 24621       | 171                                      | 142         | 73                                     | 36             | 30            | 33               | 6                   |    |
|                | 1491    | 18875            | 17343       | 183                                      | 157         | 54                                     | 23             | 18            | 19               | 5                   |    |
|                | 1492    | 4616             | 5515        | 105                                      | 209         | 22                                     | 20             | 19            | 13               | 1                   |    |
|                | 1497    | 5597             | 6524        | 174                                      | 184         | 68                                     | 44             | 32            | 35               | 12                  |    |
|                | 1499    | 9248             | 8944        | 205                                      | 147         | 84                                     | 62             | 46            | 27               | 16                  |    |
|                | 1500    | 10476            | 12232       | 369                                      | 382         | 90                                     | 55             | 40            | 30               | 15                  |    |
|                | 1502    | 13174            | 17269       | 235                                      | 289         | 55                                     | 40             | 34            | 34               | 6                   |    |
|                | 2466    | 7930             | 11635       | 89                                       | 85          | 41                                     | 25             | 15            | 27               | 10                  |    |
| <b>AVERAGE</b> |         | -                | 12558       | 13010                                    | 191         | 199                                    | 61             | 38            | 29               | 27                  | 9  |
| POST           | 1489    | 22744            | 19449       | 369                                      | 326         | 125                                    | 98             | 82            | 49               | 16                  |    |
|                | 1491    | 17607            | 14725       | 363                                      | 298         | 131                                    | 79             | 59            | 48               | 20                  |    |
|                | 1492    | 9533             | 12276       | 357                                      | 563         | 109                                    | 92             | 74            | 62               | 18                  |    |
|                | 1497    | 6756             | 6840        | 299                                      | 277         | 117                                    | 85             | 68            | 85               | 17                  |    |
|                | 1499    | 5408             | 5296        | 288                                      | 301         | 147                                    | 116            | 97            | 47               | 19                  |    |
|                | 1500    | 12347            | 10739       | 602                                      | 658         | 170                                    | 145            | 127           | 66               | 18                  |    |
|                | 1502    | 9916             | 11308       | 590                                      | 520         | 155                                    | 126            | 103           | 79               | 23                  |    |
|                | 2466    | 7042             | 4341        | 225                                      | 232         | 98                                     | 76             | 61            | 41               | 15                  |    |
| <b>AVERAGE</b> |         | -                | 11419       | 10622                                    | 387         | 397                                    | 132            | 102           | 84               | 60                  | 18 |

**SUPPLEMENTARY TABLE 6** GLIPH analysis within and across donors to identify similarities in clonotypes that expanded pre- and post- vaccination, upon BCG stimulation in both replicates, but not in MTB300 or Tetanus stimulation.

|  | Subject | Clonotypes expanded in |      |                            | GLIPH analysis |        |  |                        |                       |
|--|---------|------------------------|------|----------------------------|----------------|--------|--|------------------------|-----------------------|
|  |         | Pre                    | Post | Common<br>in<br>Pre & Post | 3-<br>mers     | 4-mers | Convergence<br>groups  | Global<br>convergences | Local<br>convergences |
| Similarity<br>between<br>Pre and<br>Post<br>within<br>each<br>donor in<br>BCG<br>stim only | 2466    | 9                      | 55   | 6                          | -              | -      | 3 groups with<br>2 peptides<br>each  | 3                      | -                     |
|  | 1502    | 20                     | 89   | 14                         | -              | -      | 7 groups with<br>2 peptides<br>each  | 7                      | -                     |
|  | 1500    | 27                     | 114  | 13                         | -              | -      | 2 groups with<br>2 peptides<br>each  | 2                      | -                     |
|  | 1499    | 12                     | 63   | 34                         | 2              | -      | 1 group with 6<br>peptides<br>2 groups with<br>5 peptides<br>each<br>3 groups with<br>2 peptides<br>each | 23                     | 20                    |
|  | 1497    | 19                     | 55   | 13                         | 1              | -      | 1 group with 5<br>peptides<br>4 groups with<br>2 peptides<br>each  | 7                      | 6                     |
|  | 1492    | 14                     | 69   | 5                          | -              | -      | 1 group with 5<br>peptides<br>3 groups with<br>2 peptides<br>each  | 4                      | 6                     |
|  | 1491    | 11                     | 52   | 7                          | -              | -      | -  | -                      | -                     |
|  | 1489    | 13                     | 65   | 17                         | -              | -      | 1 group with 2<br>peptides   | 1                      | -                     |

**SUPPLEMENTARY TABLE 7 HLA alleles expressed by each subject**

| Subject | A                 | B                 | C                 | DPB1                    | DQA1                    | DQB1                    | DRB1                    | DRB3/4/5                |
|---------|-------------------|-------------------|-------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| 1489    | A*01:01 / A*02:01 | B*08:01 / B*15:01 | C*01:02 / C*07:01 | DPB1*02:01 / DPB1*04:01 | DQA1*04:01 / DQA1*05:01 | DQB1*02:01 / DQB1*04:02 | DRB1*03:01 / DRB1*08:01 | DRB3*01:01 /            |
| 1490    | A*02:01 / A*03:01 | B*07:02 / B*44:05 | C*02:02 / C*07:02 | DPB1*03:01 / DPB1*11:01 | DQA1*02:01 / DQA1*03:01 | DQB1*02:02 / DQB1*03:02 | DRB1*04:04 / DRB1*07:01 | DRB4*01:01 / DRB4*01:01 |
| 1491    | A*02:01 / A*68:01 | B*15:01 / B*27:05 | C*02:02 / C*03:03 | DPB1*02:01 / DPB1*04:01 | DQA1*03:01 / DQA1*03:01 | DQB1*03:01 / DQB1*03:02 | DRB1*04:01 / DRB1*04:01 | DRB4*01:01 / DRB4*01:01 |
| 1492    | A*02:01 / A*32:01 | B*15:01 / B*44:02 | C*04:01 / C*05:01 | DPB1*03:01 / DPB1*20:01 | DQA1*03:01 / DQA1*04:01 | DQB1*03:02 / DQB1*04:02 | DRB1*04:01 / DRB1*08:01 | DRB4*01:01 /            |
| 1493    | A*03:01 / A*03:01 | B*35:01 / B*56:01 | C*01:02 / C*04:01 | DPB1*04:01 / DPB1*04:02 | DQA1*01:01 / DQA1*01:02 | DQB1*05:01 / DQB1*06:02 | DRB1*01:01 / DRB1*15:01 | DRB5*01:01 /            |
| 1494    | A*01:01 / A*02:01 | B*15:01 / B*55:01 | C*03:03 / C*03:04 | DPB1*04:01 / DPB1*04:02 | DQA1*03:01 / DQA1*05:01 | DQB1*03:01 / DQB1*03:02 | DRB1*04:01 / DRB1*11:04 | DRB3*02:02 / DRB4*01:01 |
| 1495    | A*25:01 / A*26:01 | B*18:01 / B*51:07 | C*12:03 / C*14:02 | DPB1*04:01 / DPB1*19:01 | DQA1*01:02 / DQA1*01:03 | DQB1*06:03 / DQB1*06:09 | DRB1*13:01 / DRB1*13:02 | DRB3*02:02 / DRB3*03:01 |
| 1496    | A*02:01 / A*33:03 | B*40:23 / B*50:01 | C*03:04 / C*06:02 | DPB1*04:02 / DPB1*14:01 | DQA1*03:01 / DQA1*03:01 | DQB1*03:01 / DQB1*03:02 | DRB1*04:01 / DRB1*09:01 | DRB4*01:01 / DRB4*01:01 |
| 1497    | A*01:01 / A*02:01 | B*44:02 / B*44:02 | C*05:01 / C*05:01 | DPB1*04:01 / DPB1*04:01 | DQA1*01:02 / DQA1*05:01 | DQB1*03:01 / DQB1*06:02 | DRB1*12:01 / DRB1*15:01 | DRB3*02:02 / DRB5*01:01 |
| 1498    | A*03:01 / A*68:01 | B*44:02 / B*57:01 | C*06:02 / C*07:12 | DPB1*01:01 / DPB1*04:01 | DQA1*01:01 / DQA1*02:01 | DQB1*03:03 / DQB1*05:01 | DRB1*01:01 / DRB1*07:01 | DRB4*01:01 /            |
| 1499    | A*01:01 / A*02:01 | B*08:01 / B*15:01 | C*03:04 / C*07:01 | DPB1*04:01 / DPB1*04:01 | DQA1*03:01 / DQA1*05:01 | DQB1*02:01 / DQB1*03:02 | DRB1*03:01 / DRB1*04:01 | DRB3*01:01 / DRB4*01:01 |
| 1500    | A*03:01 / A*03:01 | B*07:02 / B*07:02 | C*07:02 / C*07:02 | DPB1*03:01 / DPB1*03:01 | DQA1*01:01 / DQA1*01:02 | DQB1*05:01 / DQB1*06:02 | DRB1*10:01 / DRB1*15:01 | DRB5*01:01 /            |
| 1501    | A*02:01 / A*02:01 | B*15:01 / B*40:01 | C*03:03 / C*03:04 | DPB1*02:01 / DPB1*03:01 | DQA1*03:01 / DQA1*03:01 | DQB1*03:01 / DQB1*03:02 | DRB1*04:01 / DRB1*04:07 | DRB4*01:01 /            |
| 1502    | A*02:01 / A*03:01 | B*08:01 / B*44:02 | C*05:01 / C*07:01 | DPB1*04:01 / DPB1*04:01 | DQA1*01:02 / DQA1*03:01 | DQB1*03:01 / DQB1*06:02 | DRB1*04:01 / DRB1*15:01 | DRB4*01:01 / DRB5*01:01 |
| 1503    | A*02:01 / A*03:01 | B*07:02 / B*15:01 | C*03:03 / C*07:02 | DPB1*02:01 / DPB1*04:01 | DQA1*01:02 / DQA1*03:01 | DQB1*03:02 / DQB1*06:04 | DRB1*04:01 / DRB1*13:02 | DRB3*03:01 / DRB4*01:01 |
| 1504    | A*01:01 / A*02:01 | B*08:01 / B*15:01 | C*03:04 / C*07:01 | DPB1*03:01 / DPB1*04:01 | DQA1*03:01 / DQA1*05:01 | DQB1*02:01 / DQB1*03:02 | DRB1*03:01 / DRB1*04:01 | DRB3*01:01 / DRB4*01:01 |
| 2466    | A*02:01 / A*02:01 | B*40:01 / B*44:02 | C*03:04 / C*05:01 | DPB1*02:01 / DPB1*04:02 | DQA1*02:01 / DQA1*03:01 | DQB1*02:02 / DQB1*03:01 | DRB1*04:01 / DRB1*07:01 | DRB4*01:01 / DRB4*01:01 |